Recovery and distribution of incinerated aluminum packaging waste.

A study was performed into relations between physical properties of aluminum packaging waste and the corresponding aluminum scraps in bottom ash from three typical incineration processes. First, Dutch municipal solid waste incineration (MSWI) bottom ash was analyzed for the identifiable beverage can alloy scraps in the +2mm size ranges using chemical detection and X-ray fluorescence. Second, laboratory-scale pot furnace tests were conducted to investigate the relations between aluminum packaging in base household waste and the corresponding metal recovery rates. The representative packaging wastes include beverage cans, foil containers and thin foils. Third, small samples of aluminum packaging waste were incinerated in a high-temperature oven to determine leading factors influencing metal recovery rates. Packaging properties, combustion conditions, presence of magnesium and some specific contaminants commonly found in household waste were investigated independently in the high-temperature oven. In 2007, the bottom ash (+2mm fraction) from the AEB MSWI plant was estimated to be enriched by 0.1 wt.% of aluminum beverage cans scrap. Extrapolating from this number, the recovery potential of all eleven MSWI plants in the Netherlands is estimated at 720 ton of aluminum cans scrap. More than 85 wt.% of this estimate would end up in +6mm size fractions and were amenable for efficient recycling. The pot furnace tests showed that the average recovery rate of metallic aluminum typically decreases from beverage cans (93 wt.%) to foil containers (85 wt.%) to thin foils (77 wt.%). The oven tests showed that in order of decreasing impact the main factors promoting metallic aluminum losses are the packaging type, combustion temperature, residence time and salt contamination. To a lesser degree magnesium as alloying element, smaller packaging size and basic contaminations may also promote losses.

Correlation between the metabolism of hexobarbital and aminopyrine in vivo in rats.

Two model substrates for oxidative hepatic enzyme activity, namely hexobarbital and aminopyrine, were simultaneously orally administered to rats, and blood concentrations of the substrates measured by g.l.c. The apparent intrinsic clearances of hexobarbital (Cl*int.HB) and of aminopyrine (Cl*int,AM) were correlated in untreated rats, and in rats pretreated with phenobarbital, 3-methylcholanthrene, polychlorinated biphenyls or carbon tetrachloride. Cl*int,HB and Cl*int,AM were both increased by phenobarbital and polychlorinated biphenyl pretreatment. Pretreatment with 3-methylcholanthrene had hardly any effect, and carbon tetrachloride caused a strong diminution of Cl*int.HB and Cl*int.AM. When the dose of aminopyrine was decreased, both Cl*int,HB and Cl*int,AM increased. This indicated that the primary metabolite of aminopyrine, monomethylaminopyrine, inhibits cytochrome P-450. The correlation coefficient for all clearance data was 0.92 (N = 36). It was concluded that both hexobarbital and aminopyrine are metabolized in vivo by the same or closely related cytochrome P-450 isozymes, and both may be used as model substrates in vivo for metabolic conversions primarily mediated by the major phenobarbital-inducible cytochrome P-450 subspecies.

Pharmacokinetics of orally administered hexobarbital in plasma and saliva of healthy subjects.

Hexobarbital (HB) concentrations were determined in plasma and saliva of 8 healthy subjects, following oral administration of 500 mg HB-Na. Mean plasma half-lives were 3.2 +/- 0.1 h, and salivary half-lives 3.3 +/- 0.2 h. Mean plasma clearance was 22.9 +/- 2.3 1 h-1. There was a linear relationship between HB concentrations in saliva and plasma (r = 0.92). Mean salivary levels were 34 per cent of plasma levels. Salivary pH was constant throughout the experiment, 7.06 +/- 0.09. There was an inconsistent tendency of the saliva over plasma ratios to increase as a function of time. The percentage of protein binding calculated from saliva over plasma ratios was in reasonable agreement with in vitro data of equilibrium dialysis, 64.1 +/- 2.6 per cent and 65.9 +/- 0.8 per cent, respectively. The experiment was repeated in 4 subjects, and considerable intraindividual differences were shown to exist in saliva over plasma ratio, half-lives, and protein binding. It was concluded that HB elimination half-lives can relatively accurately be determined from salivary concentrations. Oral plasma clearance can only be estimated if the individual saliva over plasma ratios are known; this would require the taking of at least one blood sample during the experiment. When employing HB as a model substrate for drug metabolizing enzyme activity in vivo, the determination of its pharmacokinetic parameters, particularly oral plasma clearance as a reflection of cytochrome P-450 activity, cannot be achieved by taking saliva samples only.